Structured evidence table for Fiber Appetite Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Fiber Appetite Randomized Trial | In HC, probiotic supplementation was associated with higher vitamin D intake after one week, while in MD, a similar increase was observed after three months (trend level, p = .058). | 2 | Putz JC (2026) | Do probiotics modulate dietary intake? Pilot data from a randomized controlled sub-study of the ProBioHRV clinical trial in patients with depression and healthy controls. |
| Fiber Appetite Randomized Trial | Conclusion Probiotic supplementation did not produce consistent changes in nutrient intake but showed exploratory, time- and group-dependent patterns for selected measures, including vitamin D intake and dietary variety and diversity. | 2 | Putz JC (2026) | Do probiotics modulate dietary intake? Pilot data from a randomized controlled sub-study of the ProBioHRV clinical trial in patients with depression and healthy controls. |
| Fiber Appetite Randomized Trial | Background The gut microbiome plays a central role in human health and is strongly influenced by diet. | 2 | Putz JC (2026) | Do probiotics modulate dietary intake? Pilot data from a randomized controlled sub-study of the ProBioHRV clinical trial in patients with depression and healthy controls. |
| Fiber Appetite Randomized Trial | Probiotics can beneficially modulate the microbiome and, through the gut-brain axis, may affect mood, appetite, and food preferences. | 2 | Putz JC (2026) | Do probiotics modulate dietary intake? Pilot data from a randomized controlled sub-study of the ProBioHRV clinical trial in patients with depression and healthy controls. |
| Fiber Appetite Randomized Trial | Randomized clinical trials consistently report mean weight loss ranging from approximately 15% to more than 20% of total body weight, accompanied by improvements in glycemic control, cardiometabolic risk factors, and obesity-related comorbidities [,,]. | 3 | Zambrano-Villacres Raynier (2026) | Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance |
| Fiber Appetite Randomized Trial | As a result, pharmacotherapy is increasingly positioned as an important component of contemporary obesity treatment algorithms rather than a secondary or last-line option []. | 3 | Zambrano-Villacres Raynier (2026) | Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance |
| Fiber Appetite Randomized Trial | 20 20 20 21 22 23 24 25 26 Emerging real-world evidence indicates that a substantial proportion of individuals initiating GLP-1 receptor agonist therapy discontinue treatment within the first year []. | 3 | Zambrano-Villacres Raynier (2026) | Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance |
| Fiber Appetite Randomized Trial | 1 2 3 4 5 6 7 8 9 The therapeutic landscape of obesity management has changed profoundly with the clinical introduction and rapid uptake of glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1RAs) [,]. | 3 | Zambrano-Villacres Raynier (2026) | Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance |
Source documents